Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    Subscribe
    • Home
    • Top Stories
    • Business
    • Tech
    • Companies
    • Events
    • Announcements
    Home»BioTech»ZeptoMetrix Launches PROtrol: Quality Control Material for the Lateral Flow Immunoassay Market
    BioTech

    ZeptoMetrix Launches PROtrol: Quality Control Material for the Lateral Flow Immunoassay Market

    Marie JonesBy Marie JonesMay 16, 2023No Comments2 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    ZeptoMetrix(R) is excited to introduce PROtrol(TM), a new line of products designed for antigen-based diagnostic methods. These third-party materials mimic a true clinical specimen and can be used to evaluate and monitor the performance of antigen-based assays, including lateral flow immunoassays for infectious diseases.

    PROtrol is the only whole organism reference material to provide complete testing data. Each lot of product is supplied with the protein concentration and TCID50 value, which minimizes qualification testing. PROtrol provides better reproducibility, which optimizes the use of financial spending and processing time through the decreased need for repeat testing.

    “The rapid expansion in development of antigen-based assays has highlighted some quality challenges. Inactivated, whole organism controls designed specifically for antigen tests can equip manufacturers with the tools they need to better evaluate the performance of their assays, leading to higher quality tests on the market,” said Dr. Karuna Sharma, Vice President & Chief Scientific Officer.

    PROtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Isolate: USA-WA1/2020* is the first member of this product line (PROSARS(COV2)-587). As we move beyond the COVID-19 pandemic, ZeptoMetrix will continue to grow the PROtrol product line, providing high-quality controls to assay manufacturers seeking to expand access to inexpensive and easy-to-use diagnostics.

    “The launch and expansion of PROtrol enhances our position as the partner of choice for diagnostic test developers,” said Evangeline Gonzalez, President of Antylia Diagnostics division. “As we work with our diagnostic partners, ZeptoMetrix is pleased with the role that PROtrol plays to give patients around the world more access to diagnostic testing.”

    More information on how to order the new PROtrol and additional ZeptoMetrix products can be found at: https://www.zeptometrix.com

    About ZeptoMetrix(R)
    ZeptoMetrix(R) is an established industry leader in the design, development, and delivery of innovative, quality solutions to the infectious disease diagnostics market. Our expertise and abilities in molecular diagnostics, including external quality controls, verification panels, proficiency panels, customized and OEM products/services have set the industry standard for performance and reliability and make ZeptoMetrix the preferred choice for independent third-party quality control materials.

    Links:
    * (PROSARS(COV2)-587): product page
    https://www.zeptometrix.com/products/protrolt-sars-cov-2-isolate-usa-wa1-2020-1-ml

    Contact Information
    Andrew Zenger
    Global Product Manager
    andrew.zenger@antylia.com
    (716) 715-7417

    Related Files
    PROSARS(COV2)-587 Product Insert.pdf https://cdn.newswire.com/files/x/f7/75/6f2724d112cd754a1e946ada2060.pdf
    ZeptoMetrix Launches PROtrol.pdf https://cdn.newswire.com/files/x/94/c9/f6adf7dcd8a49a3ac3d828c851a5.pdf

    ZeptoMetrix
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticlePalladium One Identifies Additional Chonolith / Feeder Dyke Structures, Field Season Initiated on the Tyko Nickel Project, Canada
    Next Article Unitea raises $7m in latest funding round

    Related Posts

    AcroMeta to Enter Ambient Temperature Cellular Logistics Through Strategic Partnership with Macro HRD SG Pte. Ltd.

    September 7, 2026

    Fosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 Billion

    September 7, 2026

    CMS (867.HK/8A8.SG): Innovative Drug Lumirix(R) Approved in China for Additional Indication of Atopic Dermatitis (AD)

    September 4, 2026
    Add A Comment
    Leave A Reply Cancel Reply

    © 2026 BusinessNewsAsia.com
    • About Us
    • Contact Us
    • BusinessNews.ph
    • AsiaPEVC.com
    • DevFiNews.com
    • RenewableEnergy.ph

    Type above and press Enter to search. Press Esc to cancel.